Leukocyte DNA Methylation Signature Differentiates Pancreatic Cancer Patients from Healthy Controls

Katrina S Pedersen, William R Bamlet, Ann L Oberg, Mariza de Andrade, Martha E Matsumoto, Hui Tang, Stephen N Thibodeau, Gloria M Petersen and Liang Wang

PLOS ONE, 2011, vol. 6, issue 3, 1-9

Abstract: Pancreatic adenocarcinoma (PaC) is one of most difficult tumors to treat. Much of this is attributed to the late diagnosis. To identify biomarkers for early detection, we examined DNA methylation differences in leukocyte DNA between PaC cases and controls in a two-phase study. In phase I, we measured methylation levels at 1,505 CpG sites in treatment-naïve leukocyte DNA from 132 never-smoker PaC patients and 60 never-smoker healthy controls. We found significant differences in 110 CpG sites (false discovery rate

Date: 2011
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0018223 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 18223&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0018223

DOI: 10.1371/journal.pone.0018223

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().